Streetbeat News

Products Services

IMGN

ImmunoGen Inc (NASDAQ:IMGN) announced positive results from the Phase 3 MIRASOL trial of Elahere, showing a statistically significant improvement in Progression Free Survival (PFS) compared to chemotherapy in patients with platinum-resistant ovarian cancer. The results were presented at the 2023 ASCO Annual Meeting. IMGN shares are up 7.86% at $15.50 during the premarket session.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:27 pm

BIOC

Biocept presented a scientific poster at the 2023 ASCO Meeting, highlighting a real-world retrospective study that showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:25 pm

AKRO

Akero Therapeutics reported that its SYMMETRY study met safety and tolerability endpoints, leading to higher trading of its shares.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:23 pm

DAWN

Day One Biopharmaceuticals (NASDAQ:DAWN) announced positive data from the Phase 2 FIREFLY-1 trial of tovorafenib (DAY101) at the 2023 ASCO Annual Meeting. The company also initiated a rolling New Drug Application (NDA) to the FDA for tovorafenib as a monotherapy in pediatric low-grade glioma (pLGG). DAWN shares are up 23.20% in premarket trading.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:23 pm

IMGN

ImmunoGen shares are trading higher after the company provided an update on its ELAHERE treatment for ovarian cancer.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:20 pm

INAB

IN8bio announced that 100% of treated patients in the INB-200 Phase 1 study for glioblastoma have exceeded historical median progression-free survival. The company is on track to complete enrollment in 2023 with updated data expected later this year.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:19 pm

TSM

TSMC has begun pre-production of its 2nm chips and aims for mass production by 2025. This development could potentially strengthen TSMC's position as a leading semiconductor manufacturer.

Portfolio Pulse from Charles Gross

June 05, 2023 | 12:19 pm

PRTG

Portage Biotech presented updated interim data for its lead iNKT Engager, PORT-2, at the 2023 ASCO Meeting, showing early evidence of single agent activity and meaningful reduction of target lesions. The company plans to expand the Phase 1 trial to evaluate higher dose levels, with data expected by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:18 pm

AZN

AstraZeneca's Tagrisso reduces the risk of death by 51% in certain early-stage non-small cell lung cancer patients, according to the ADAURA Phase 3 trial. In 2022, Tagrisso generated $5.4 billion in revenue for the company.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:15 pm

IMMP

Immutep presented final data from its 2nd line head and neck squamous cell carcinoma study at the 2023 ASCO Meeting, showcasing the potential of its treatment.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:13 pm